Novel prodrug supramolecular nanoparticles capable of rapid mitochondrial-targeting and ROS-responsiveness for pancreatic cancer therapy-Reference-Cited by-同舟云学术

Novel prodrug supramolecular nanoparticles capable of rapid mitochondrial-targeting and ROS-responsiveness for pancreatic cancer therapy

Published:2022 Issue:26 Volume:46 Page:12632-12640
ISSN:1144-0546
Container-title:New Journal of Chemistry
language:en
Short-container-title:New J. Chem.

Author:

Huang Zheng¹²^ORCID,Gao Lixia¹,Guo Fang¹,Li Dan¹,Tang Yan¹,Hu Huaisong¹,Luo Yafei¹,Tang Dianyong¹^ORCID,Wang Bochu²^ORCID,Zhang Yimei¹²^ORCID

Affiliation:

1. National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, College of Pharmacy & International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, Chongqing 402160, China

2. Key Laboratory of Bio-theological Science and Technology of Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400045, China

Abstract

Mitochondrial dysfunction is a feature of cancer cells and targeting cancer mitochondria has emerged as a promising anticancer therapy.

Funder

Natural Science Foundation of Chongqing

National Natural Science Foundation of China

Chongqing University of Arts and Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,General Chemistry,Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2022/NJ/D2NJ01157C